Immune cell therapy aims to stop BK virus bladder bleeding in transplant patients
NCT ID NCT07638332
First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 4 times
Summary
This early-phase trial tests a new treatment called LB-DTK-BKV for people who develop painful bladder bleeding (hemorrhagic cystitis) from BK virus after a stem cell transplant. The treatment uses immune cells from a donor that are trained to attack the virus. About 42 children and adults will receive two infusions of these cells and be monitored for 6 months to see if the virus levels drop and if side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LB-DTK-BKV (BK virus-specific T cells from a donor)
- What this could lead to
- If it works, this could offer a targeted treatment for painful bladder bleeding caused by BK virus after stem cell transplants, reducing the need for harsh supportive care.
- What could go wrong
- This is an early phase 1/2 trial with only 42 participants, so results may not apply widely. The treatment involves donor cells, which carry risks like infusion reactions or graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMORRHAGIC CYSTITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, Seoul, 05505, South Korea
-
Chonnam National University Hwasun Hospital
Hwasun, 58128, South Korea
-
Ewha Womans University Seoul Hospital
Seoul, 07804, South Korea
-
Kyungpook National University Chilgok Hospital
Daegu, 41404, South Korea
-
National Cancer Center Korea
Goyang-si, 10408, South Korea
-
Samsung Medical Center
Seoul, Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, Seoul, 03080, South Korea
-
Severance Hospital
Seoul, Seoul, 03722, South Korea
-
Ulsan University Hospital
Ulsan, 44033, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.